| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.97▲ | 1.97▲ | 1.97▲ | 2.03▼ | 2.61▼ |
| MA10 | 1.97▲ | 2.01▼ | 2.01▼ | 2.18▼ | 3.07▼ |
| MA20 | 2.02▼ | 1.96▲ | 1.98▲ | 2.58▼ | 7.49▼ |
| MA50 | 1.98▲ | 2.05▼ | 2.11▼ | 3.17▼ | 31.93▼ |
| MA100 | 2.09▼ | 2.31▼ | 2.51▼ | 8.56▼ | 24.13▼ |
| MA200 | 2.44▼ | 2.68▼ | 2.78▼ | 37.10▼ | 51.34▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | 0.006▲ | 0.013▲ | 0.006▲ | 0.711▲ |
| RSI | 50.109▲ | 48.354▼ | 45.896▼ | 29.322▼ | 36.198▼ |
| STOCH | 56.841 | 16.739▼ | 34.381 | 15.422▼ | 1.699▼ |
| WILL %R | -50.000 | -64.516 | -45.455 | -77.397▼ | -97.778▼ |
| CCI | 42.551 | -33.333 | 10.067 | -82.057 | -95.022 |
| ▲ MACD | $APVO MACD(12,26,9) Crossed Above Signal Line | Set Alert |
|
Wednesday, August 13, 2025 05:55 AM
Aptevo Therapeutics (APVO) reinforced the strategic importance of its preclinical asset APVO442-an investigational CD3-engaging bispecific ...
|
|
Wednesday, August 13, 2025 05:30 AM
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS ...
|
|
Monday, August 11, 2025 05:27 AM
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 2.05 | 2.05 | 1.92 | 2.00 | 75,249 |
| 14/08/25 | 1.78 | 2.20 | 1.7197 | 2.04 | 263,746 |
| 13/08/25 | 2.06 | 2.06 | 1.86 | 1.91 | 554,568 |
| 12/08/25 | 2.13 | 2.18 | 2.05 | 2.06 | 89,091 |
| 11/08/25 | 2.19 | 2.225 | 2.10 | 2.15 | 101,802 |
| 08/08/25 | 2.15 | 2.26 | 2.14 | 2.26 | 44,855 |
| 07/08/25 | 2.15 | 2.1931 | 2.0992 | 2.14 | 51,747 |
| 06/08/25 | 2.41 | 2.47 | 2.17 | 2.17 | 104,965 |
| 05/08/25 | 2.55 | 2.60 | 2.3624 | 2.45 | 122,466 |
| 04/08/25 | 2.70 | 2.80 | 2.55 | 2.59 | 94,026 |
|
|
||||
|
|
||||
|
|